CELU
Celularity Inc.
There isn't enough reported data to score CELU yet.
CELU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Unavailable | |
| Unavailable |
CELU's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
CELU PE Valuation
CELU has no meaningful PE right now: it lost money over the past year.
CELU Forward outlook
There aren't enough analyst estimates for CELU to show an outlook.
CELU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.69 | +$1.48 |
| Q1 2026 | -$2.73 | -$0.28 |
| Q4 2025 | -$3.59 | -$0.95 |
CELU is still losing money, but far less than before: $1.69 per share over the past year, against $9.60 at its worst in late 2023.
CELU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.4M | -5.3% |
| Q1 2026 | $3.8M | -66% |
| Q4 2025 | $4.1M | -77% |
| Q3 2025 | $5.3M | -43% |
| Q2 2025 | $5.7M | -53% |
| Q1 2025 | $11.4M | -22% |
| Q4 2024 | $18.1M | +50% |
| Q3 2024 | $9.3M | +146% |
CELU's revenue has slid since its 2024 peak: $5M last quarter, down 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -78% | +199 points |
| Q1 2026 | -263% | -172 points |
| Q4 2025 | -537% | -486 points |
| Q3 2025 | -244% | -120 points |
| Q2 2025 | -277% | -193 points |
| Q1 2025 | -92% | -42 points |
| Q4 2024 | -51% | -161 points |
| Q3 2024 | -124% | +2498 points |
CELU's operating margin was −78% last quarter, up 199 points from the same quarter a year ago.
CELU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$5.1M | -432% |
| Q4 2024 | $1.5M | +$6.5M |
| Q3 2024 | -$179K | +$8.4M |
| Q2 2024 | -$3.5M | +$7.6M |
| Q1 2024 | -$4.4M | +$10.8M |
| Q4 2023 | -$4.9M | +$25.4M |
| Q3 2023 | -$8.6M | +$30.7M |
| Q2 2023 | -$11.1M | +$26.7M |
CELU has burned cash in almost every quarter: −$3M over the past year, against −$13M the year before.
CELU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -955K shares |
| 1 year | +25% | +5.8M shares |
| 3 years | +89% | +13.8M shares |
| 5 years | +3561% | +28.5M shares |
CELU has 29M diluted shares, up 25% from a year ago.
CELU Net Leverage
CELU's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CELU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.3 | Neutral |
| Stochastic | 6.1 | Oversold |
CELU's weekly RSI is 39 (neutral) and its Stochastic is 6 (oversold).
CELU PE vs Healthcare Sector
| Metric | CELU | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CELU has no meaningful PE right now: it lost money over the past year.
CELU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.13 | 40% below |
| 20 week MA | $1.04 | 35% below |
| 50 week MA | $1.12 | 39% below |
| 100 week MA | $1.63 | 58% below |
| 200 week MA | $2.85 | 76% below |
CELU is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
CELU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $99.5 | $118.0 | +19% |
| 2021 | $118.0 | $47.0 | -60% |
| 2022 | $47.0 | $11.5 | -76% |
| 2023 | $11.5 | $2.47 | -79% |
| 2024 | $2.47 | $2.24 | -9.3% |
| 2025 | $2.24 | $1.34 | -40% |
| 2026 YTD | $1.34 | $0.68 | -49% |
CELU has finished five years in a row lower, and it's down 49% so far in 2026.